Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 known ✓ | Q99720 | 9/20 | 0.63 |
| ▸ | SLC6A4 known ✓ | P31645 | 2/20 | 0.58 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.63 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.63 |
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3174249 | 0.98 | SIGMAR1 (0.65) | SIGMAR1TAAR1SLC18A2NPC1RAB9A | |
| SCHEMBL125441 | 0.98 | SIGMAR1 (0.65) | SIGMAR1TAAR1SLC18A2NPC1RAB9A | |
| Hydrochloric Acid SCHEMBL219711 | 0.96 | SIGMAR1 (0.63) | SIGMAR1TAAR1SLC18A2NPC1RAB9A | |
| Iodide SCHEMBL221293 | 0.96 | SIGMAR1 (0.63) | SIGMAR1TAAR1SLC18A2NPC1RAB9A | |
| Sulfuric Acid SCHEMBL28341061 | 0.88 | NPC1 (0.58) | SIGMAR1TAAR1SLC18A2NPC1RAB9A | |
| Hydroxyamphetamine SCHEMBL7041719 | 0.81 | TAAR1 (0.66) | SIGMAR1TAAR1SLC18A2SLC6A4 | |
| Methamphetamine SCHEMBL27438559 | 0.80 | SIGMAR1 (0.95) | SIGMAR1TAAR1SLC18A2NPC1RAB9A | |
| Methamphetamine SCHEMBL28513614 | 0.80 | SIGMAR1 (0.95) | SIGMAR1TAAR1SLC18A2NPC1RAB9A | |
| SCHEMBL21243273 | 0.79 | SIGMAR1 (0.73) | SIGMAR1TAAR1SLC18A2NPC1RAB9A | |
| SCHEMBL30624762 | 0.79 | SIGMAR1 (0.71) | SIGMAR1TAAR1SLC18A2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 312 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12576067-B2 | Methods and compositions for treatment of mydriasis | OPUS GENETICS, INC. (US) | 2026-03-17 | — | — | US | claimed |
| US-12576066-B2 | Methods and compositions for treatment of mydriasis | OPUS GENETICS, INC. (US) | 2026-03-17 | — | — | US | claimed |
| US-20250161275-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF MYDRIASIS | OPUS GENETICS, INC. | 2025-05-22 | — | — | US | claimed |
| US-20250161274-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF MYDRIASIS | OPUS GENETICS, INC. | 2025-05-22 | — | — | US | claimed |
| US-10123996-B2 | Macrocyclic lactone compounds and methods for their use | ELIXIR MEDICAL CORPORATION (US) | 2018-11-13 | — | — | US | claimed |
| WO-2018152554-A1 | ANTITUSSIVE COMPOSITIONS AND METHODS | ATTENUA, INC. (US) | 2018-08-23 | — | — | WO | claimed |
| EP-3328383-A1 | ANTITUSSIVE COMPOSITIONS AND METHODS | Attenua, Inc. (US) | 2018-06-06 | — | — | EP | claimed |
| CN-107847493-A | ANTITUSSIVE COMPOSITIONS AND METHODS | 阿提努公司 | 2018-03-27 | — | — | CN | claimed |
| US-20170273957-A1 | ANTITUSSIVE COMPOSITIONS AND METHODS | ATTENUA, INC. | 2017-09-28 | — | — | US | claimed |
| US-9724340-B2 | Antitussive compositions and methods | ATTENUA, INC. (US) | 2017-08-08 | — | — | US | claimed |
| EP-1480677-A2 | COMPOSITION FOR STABILIZING HYALURONIC ACID | IOLTECH (FR) | 2004-12-01 | — | — | EP | claimed |
| US-20030133986-A1 | Compositions for stabilizing poly (carboxylic acids) | TSAO FU-PAO (US) | 2003-07-17 | — | — | US | claimed |
| WO-2003043660-A2 | COMPOSITION FOR STABILIZING HYALURONIC ACID | NOVARTIS AG (CH) | 2003-05-30 | — | — | WO | claimed |
| EP-1011415-A1 | NON-INVASIVE METHOD FOR DIAGNOSING ALZHEIMER'S DISEASE IN A PATIENT | BETH ISRAEL HOSPITAL (US) | 2000-06-28 | — | — | EP | claimed |
| US-5704369-A | Non-invasive method for diagnosing Alzeheimer's disease in a patient | BETH ISRAEL HOSPITAL ASSOCIATION, INC. (US) | 1998-01-06 | — | — | US | claimed |
| EP-1011415-A4 | NON-INVASIVE METHOD FOR DIAGNOSING ALZHEIMER'S DISEASE IN A PATIENT | BETH ISRAEL HOSPITAL (US) | 1997-08-18 | — | — | EP | claimed |
| WO-1996003070-A1 | NON-INVASIVE METHOD FOR DIAGNOSING ALZHEIMER'S DISEASE IN A PATIENT | BETH ISRAEL HOSPITAL ASSOCIATION (US) | 1996-02-08 | — | — | WO | claimed |
| EP-0351897-A2 | Skin penetration system for salts of amine-functional drugs | THE PROCTER & GAMBLE COMPANY (US) | 1990-01-24 | — | — | EP | claimed |
| EP-0046270-B1 | NOVEL DERIVATIVES OF BIO-AFFECTING PHENOLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITION CONTAINING THEM | INTERx RESEARCH CORPORATION (US) | 1986-05-21 | — | — | EP | claimed |
| US-3968245-A | Sympathomimetic topical and percutaneous administration with halogenated promoters | ALZA CORPORATION (US) | 1976-07-06 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10123996-B2 | Macrocyclic lactone compounds and methods for their use | CHRM2, CHRM1, CHRM5 | SIGMAR1 688/4885SLC6A4 4352/4885TAAR1 4388/4885 |
| US-20170273957-A1 | ANTITUSSIVE COMPOSITIONS AND METHODS | CHRNA7, CHRNA1, CHRNG | SIGMAR1 242/4885SLC6A4 1141/4885TAAR1 92/4885 |
| US-12576066-B2 | Methods and compositions for treatment of mydriasis | ADRA1D, ADRB2, ADRA2B | SIGMAR1 333/4885SLC6A4 59/4885TAAR1 132/4885 |
| US-20250161274-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF MYDRIASIS | ADRB2, ADRB3, ADRB1 | SIGMAR1 855/4885SLC6A4 2699/4885TAAR1 536/4885 |
| US-20250161275-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF MYDRIASIS | ADRB2, ADRB3, ADRB1 | SIGMAR1 855/4885SLC6A4 2699/4885TAAR1 536/4885 |
| US-12576067-B2 | Methods and compositions for treatment of mydriasis | ADRA1D, ADRB2, ADRA2B | SIGMAR1 332/4885SLC6A4 56/4885TAAR1 132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.